Mechanism Of Action Of Pre-Meal Consumption Of Whey Protein On Glycemic Control In Young Adults Tina Akhavan, Bohdan L. Luhovyy, Shirin Panahi, Ruslan Kubant, Peter H. Brown, G. Harvey Anderson PII: DOI: Reference:
S0955-2863(13)00183-6 doi: 10.1016/j.jnutbio.2013.08.012 JNB 7093
To appear in:
The Journal of Nutritional Biochemistry
Received date: Revised date: Accepted date:
12 February 2013 27 August 2013 30 August 2013
Please cite this article as: Akhavan Tina, Luhovyy Bohdan L., Panahi Shirin, Kubant Ruslan, Brown Peter H., Anderson G. Harvey, Mechanism Of Action Of Pre-Meal Consumption Of Whey Protein On Glycemic Control In Young Adults, The Journal of Nutritional Biochemistry (2013), doi: 10.1016/j.jnutbio.2013.08.012
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
T
MECHANISM OF ACTION OF PRE-MEAL CONSUMPTION OF WHEY PROTEIN
MA
NU
SC
RI P
ON GLYCEMIC CONTROL IN YOUNG ADULTS1,2
Tina Akhavana, Bohdan L. Luhovyya, Shirin Panahia, Ruslan Kubanta, Peter H. Brownb, G.
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto,
CE
a
PT
ED
Harvey Andersona*
b
AC
Ontario, Canada (TA, BLL, SP, RK, GHA) Kraft Foods Global LLC, US (PHB)
*Corresponding author. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, 150 College Street, M5S 3E2, Toronto, ON, Canada. Tel: (416) 978-1832, Fax: (416) 978-5882, E-mail:
[email protected] 1
We would like to thank Kraft Foods Global LLC for providing the whey protein and McCain
Foods Ltd. (Toronto, ON) for providing pizza for the experimental meals. This project has been supported by a Collaborative Research and Development Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) and Kraft Canada Inc.
1
ACCEPTED MANUSCRIPT 2
Author disclosure: T Akhavan, B.L. Luhovyy, S Panahi, R Kubant, P.H. Brown, and G.H
Anderson have no conflicts of interest to report. PHB is an employee of Kraft Foods Global LLC
RI P
T
(Chicago, IL).
RUNNING TITLE: Whey protein consumption and glycemia
SC
WORD COUNT: 5354; NUMBER OF FIGURES: 5; NUMBER OF TABLES: 2
NU
ABBREVIATION USED: WP (whey protein), GIP (gastric inhibitory polypeptide), GLP-1 (glucagon-like peptide-1), CCK (cholecystokinin), PYY (peptide tyrosine-tyrosine), CHO
MA
(carbohydrate), BMI (body mass index), VAS (visual analogue scales), ANOVA (analysis of variance), Insulin SECretion (ISEC), DPP-IV (dipeptidyl peptidase IV), BBB (blood-brain
AC
CE
PT
ED
barrier), CNS (central nervous system)
2
ACCEPTED MANUSCRIPT 1 2
ABSTRACT Whey protein (WP), when consumed in small amounts prior to a meal, improves postmeal glycemic control more than can be explained by insulin-dependent mechanisms alone. The
4
objective of the study was to identify the mechanism of action of WP beyond insulin on the
5
reduction of post-meal glycemia. In a randomized crossover study, healthy young men received
6
preloads (300 mL) of WP (10 and 20 g), glucose (10 and 20 g) or water (control). Paracetamol
7
(1.5 g) was added to the preloads to measure gastric emptying. Plasma concentrations of
8
paracetamol, glucose, and ß-cell and gastrointestinal hormones were measured before preloads
9
(baseline) and at intervals before (0-30 min) and after (50-230 min) a preset pizza meal (12
MA
NU
SC
RI P
T
3
kcal/kg). Whey protein slowed pre-meal gastric emptying rate compared to the control and 10 g
11
glucose (P < 0.0001), and induced lower pre-meal insulin and C-peptide than the glucose
12
preloads (P < 0.0001). Glucose, but not WP, increased pre-meal plasma glucose concentrations
13
(P < 0.0001). Both WP and glucose reduced post-meal glycemia (P = 0.0006) and resulted in
14
similar CCK, amylin, ghrelin and GIP responses (P < 0.05). However, compared with glucose,
15
WP resulted in higher post-meal GLP-1 and PYY and lower insulin concentrations, without
16
altering insulin secretion and extraction rates. For the total duration of this study (0-230 min),
17
WP resulted in lower mean plasma glucose, insulin and C-peptide, but higher GLP-1 and PYY
18
concentrations than the glucose preloads. In conclusion, pre-meal consumption of WP lowers
19
post-meal glycemia by both insulin-dependent and insulin-independent mechanisms.
AC
CE
PT
ED
10
20 21 22 23
3
ACCEPTED MANUSCRIPT 24 25
INTRODUCTION When consumed with carbohydrate (CHO), proteins in general [1, 2] and milk proteins specifically [3, 4] reduce glycemic response compared with CHO alone. This effect has been
27
attributed to the is insulinotropic effect of milk proteins [5, 6], and more specifically to whey
28
protein (WP) [7]. The addition of WP [3, 8] or whey peptides [4] to a glucose drink or CHO
29
meal reduces glycemic response, which has been attributed to its rapid digestion [9], and release
30
of amino acids and bioactive peptides during digestion stimulate release of insulin [10], and
31
many gastrointestinal hormones [7].
RI P
SC
NU
Proteins are known to be insulinotrophic but whether WP is more so, as has been
MA
32
T
26
suggested, and it is the only cause of the lowered glycemia after its consumption is unclear. A
34
breakfast and lunch, each containing 28 g of WP and 50 g CHO served to adults with T2D,
35
resulted in higher blood insulin concentrations after both breakfast and lunch and lower glucose
36
after the lunch than when the meals contained lean ham [3]. Additionally, 50 g WP in a meal
37
lowered glycemia more than a similar amount of protein from turkey or egg albumin, and
38
resulted in higher insulin concentrations than the meals with turkey, egg albumin and tuna over
39
240 min [11].
PT
CE
AC
40
ED
33
However, the reduced glycemia after protein consumption either with CHO [2] or alone
41
[9, 12] may be due to increased insulin release but also to release of gut hormones that delay
42
stomach emptying and to the release of incretins that increase efficacy of insulin [7]. Small
43
amounts (as low as 9-10 g) consumed 30 min prior to a meal [13] reduce post-meal
44
concentrations of both glucose and insulin, indicating that insulin cannot be the only cause of the
45
reductions. Only one study has related decreased post-meal glycemia to slower gastric emptying.
4
ACCEPTED MANUSCRIPT 46
Pre-meal consumption of 55 g WP increased glucagon-like peptide-1 (GLP-1) and delayed
47
gastric emptying more than when consumed with a small CHO meal [14]. Therefore, the hypothesis of this study was that WP consumed alone prior to a meal
T
48
improves post-meal glycemic control by both insulin-dependent and -independent mechanisms.
50
The objective was to describe and compare the effect of WP and glucose consumed 30 min
51
before a fixed meal in healthy men on pre- and post-meal and plasma concentrations of glucose,
52
insulin, gastrointestinal hormones regulating stomach emptying and incretins involved in
53
potentiating insulin efficacy and on pre-meal gastric emptying rate.
54
METHODS AND MATERIALS
56
Participants
In a randomized crossover design, 10 men (18-29 y, 18.5-29.4 kg/m2) received preloads
PT
57
ED
55
MA
NU
SC
RI P
49
(300 mL) of WP (10 and 20 g), glucose (10 and 20 g) or water (control). Paracetamol (1.5 g) was
59
added to the preloads to measure gastric emptying. Plasma concentrations of paracetamol,
60
glucose, ß-cell hormones and gastrointestinal hormones were measured before preloads
61
(baseline) as well as at intervals before (0-30 min) and after (50-230 min) a preset pizza meal (12
62
kcal/kg).
63
AC
CE
58
Participants were recruited through advertisements posted on the University of Toronto
64
campus. At initial contact by phone or e-mail, eligibility requirements were described to the
65
potential subjects and they were asked for their age, body weight, height, if they smoke or were
66
taking any medications. Breakfast skippers, smokers, dieters and individuals with diabetes or
67
other metabolic diseases were ineligible to participate in the study. Individuals who fulfilled
68
eligibility requirements were asked to come to the Department for a second screening to
5
ACCEPTED MANUSCRIPT complete questionnaires regarding food habits, food preference and dietary restraint [15] and to
70
read and sign the consent form. Their height and weight were measured to calculate their body
71
mass index (BMI). Qualified subjects were invited to participate in the study. Subjects were
72
financially compensated for completing the study. The procedures of the study were approved by
73
the Human Subject Review Committee, Ethics Review Office at the University of Toronto.
RI P
Based on previous clinical studies on gut hormones with the sample size required for
SC
74
T
69
blood glucose response [4, 16, 17], 10 male subjects, aged 18-29 years with a BMI between
76
18.5-24.9 kg/m2, were recruited and completed the sessions.
NU
75
79
Protocol
Experimental sessions took place at the Department of Nutritional Sciences at University
ED
78
MA
77
of Toronto and subjects participated in the study twice per week. Similar to our previous study
81
[13], a breakfast (300 kcal) of a single serving of a ready-to-eat breakfast cereal (Honey Nut
82
Cheerios; General Mills, Mississauga, Canada), a 250-mL box of 2% milk (Sealtest Skim Milk,
83
Markham, Canada) and a 250-mL box of orange juice (Tropicana Products Inc, Bradenton, FL)
84
was provided to subjects to be consumed at their preferred time in the morning (0600–0900)
85
after a 10-h overnight fast. Subjects were asked not to consume anything between the breakfast
86
and the study session 4 h later (1000 to 1300). Participants were permitted to consume water
87
until 1 h before the session. Each subject arrived at the same chosen time for each session. They
88
were instructed to refrain from alcohol consumption and any unusual exercise and activity the
89
night before the study sessions.
AC
CE
PT
80
90
Upon arrival, subjects filled out the Sleep Habits and Stress Factors Questionnaire and
91
Food Intake and Activity Questionnaire forms. Visual Analogue Scales (VAS) questionnaires
6
ACCEPTED MANUSCRIPT 92
were then completed to measure Physical Comfort and Fatigue/Energy [16, 18]. If they reported
93
significant deviations from their usual patterns, they were rescheduled. Following completion of the VAS questionnaires, an indwelling intravenous catheter was
T
94
inserted in the antecubital vein by a registered nurse and a baseline blood sample obtained.
96
Immediately after, participants drank one of the five preloads within 5 min, followed by
97
completion of a palatability VAS (at 5 min). Blood samples were collected at 10, 20 and 30 min
98
(pre-meal) and 50, 60, 70, 80, 110, 140, 170, 200 and 230 min (post-meal).
NU
SC
RI P
95
99
101
Preloads
MA
100
Pre-meal drinks included iso-volumetric amounts (300 mL) of 10 and 20 g intact WP (NZMP Whey Protein Concentration 392, Fonterra Co- operative Group Limited, New Zealand),
103
and 10 and 20 g glucose control (D-Glucose Monohydrate , Grain Process Enterprises LTD.
104
Scarborough, ON) and a water control. Paracetamol (1.5 g, Panadol, GlaxoSmithKline) was also
105
dissolved in each of the five preloads. Preloads were served chilled with an additional 100 mL
106
of water (in a separate glass) to be consumed upon completion of the drinks to reduce aftertaste.
107
Lemon flavor (0.5 mL, Flavorganics, Newark, NJ), lemon juice (2 tsp, Equality; The Great
108
Atlantic and Pacific Company of Canada Ltd, Toronto, Canada) and sucralose (0.15 g, McNeil
109
Specialty Products Company, New Brunswick, NJ) were added to the drinks to equalize
110
palatability and sweetness and to blind the subjects to the preloads.
AC
CE
PT
ED
102
111 112 113 114
Blood Parameters Blood was collected in 8.5 mL BD™ P800 tubes (BD Diagnostics, Franklin Lakes, NJ) containing spray-dried K2EDTA anticoagulant and proprietary additives to prevent their
7
ACCEPTED MANUSCRIPT immediate proteolytic activity. The tubes were centrifuged at 1300 RCF for 20 min at 4°C.
116
Collected plasma samples were aliquoted in Eppendorf tubes and stored at -70 C for analyses.
117
Plasma concentrations of glucose, paracetamol, insulin, C-peptide, amylin, ghrelin, GLP-1, GIP,
118
CCK and PYY were measured.
RI P
T
115
Plasma glucose was measured using the enzymatic hexokinase method (Roche
119
Diagnostic, Laval, QC, Canada). Insulin and C-peptide were assessed with
121
electrochemiluminescence assays ―ECLIA‖ (Roche Diagnostic, Laval, QC, Canada). These
122
analyses were performed by the Pathology and Laboratory Medicine Division at Mount Sinai
123
Hospital (Toronto, ON, Canada). However, the remaining biomarkers were measured at the
124
Department of Nutritional Sciences, University of Toronto.
MA
NU
SC
120
Free paracetamol was determined with a commercially-available paracetamol
126
(acetaminophen) enzymatic assay (Cambridge Life Sciences, Ely, Cambridge, UK). Human
127
active GLP-1 (# EGLP-35K), total ghrelin (# EZGRT-89K), total GIP (# EZHGIP-54K), total
128
PYY (# EZHPYYT66K) and total amylin (# EZHAT-51K) were measured with ELISA kits
129
(Millipore, Billerica, MA). Human CCK was measured by enzyme immunoassay (# EIA-CCK-1,
130
RayBiotech Inc, Norcross, GA).
AC
CE
PT
ED
125
Plasma concentrations of glucose, insulin and C-peptide were measured at all sampling
131 132
times, however, due to the high cost of the kits and measurements, plasma concentrations of
133
hormones were measured at only baseline, 20 and 30 min (pre-meal) and 60, 80, 140 and 230
134
min (post-meal).
135 136
Meal
8
ACCEPTED MANUSCRIPT Subjects were served a preset pizza meal (12 kcal/ kg body weight of subjects) with a
138
bottled spring water (500 mL Crystal Springs) at 30 min because the primary objective of the
139
study was to determine the mechanisms of pre-meal consumption of WP on post-meal glycemic
140
control. Subjects were given 20 min to consume the pizza meal. Pizza (McCain Foods Ltd.
141
Florenceville, NB) was served at all sessions after cooking from frozen according to
142
manufacturer‘s directions. Detailed information of the nutrient content of the pizza and method
143
of cooking was reported previously [16, 18]. They completed a VAS questionnaire on the
144
palatability of the pizza after finishing the pizza meal. Because there were no differences in
145
palatability or appetite among the preloads, the results are not reported here.
MA
NU
SC
RI P
T
137
148
Data Analysis and Calculation
A two-way repeated measures analysis of variance (ANOVA), using SAS Proc Mixed
PT
147
ED
146
model followed by Tukey‘s post hoc test, was conducted on pre-meal (0-30 min), post-meal (50-
150
230 min) and total (0-230 min) mean plasma concentrations of the dependent measures to test for
151
time and preload effects. Means of the pre-meal, post-meal and total concentrations were used as
152
an estimate of response in treatment measures rather than area under the curve because post-meal
153
concentrations were above baseline and varied in response to preload amount and composition.
154
When an interaction was found, one-way ANOVA was performed to identify the effect of
155
preload at each time of sampling. One-way ANOVA was also used to make summary mean
156
comparisons. Because there were no differences at baseline glucose, hormone and paracetamol
157
concentrations, only the absolute concentrations are reported. Significance was set at P < 0.05.
158
Data were presented as mean ± standard error of the mean (SEM).
AC
CE
149
9
ACCEPTED MANUSCRIPT 159 160
The pre-hepatic insulin secretion (Figure 2) was calculated from deconvolution of plasma concentrations of C-peptide by using the ISEC computer program [19].
RESULTS
163
Participants
Ten subjects completed the study. After completing the study and measurements of the
SC
164
RI P
162
T
161
entire samples, two subjects had higher mean insulin (704 ± 341 vs. 197 ± 5 pmol/L) and C-
166
peptide (2293 ± 797 vs. 1455 ± 26 pmol/L) concentrations compared to other subjects both at
167
baseline and throughout the sessions, most possibly due to either consumption of food before
168
starting the sessions, or physiological differences such as hyperinsulinemia [8]. They were
169
informed and asked to check with their physicians. They were excluded from the analyses,
170
therefore the results are based on eight healthy males with a mean age of 22.9 ± 1.2 y, body
171
weight of 66.4 ± 2.9 kg, height of 1.7 ± 0.0 m, and BMI of 21.8 ± 0.6 kg/m2.
172
Plasma glucose, insulin, C-peptide and amylin
MA
ED
PT
CE
Pre-meal, post-meal and total mean concentrations of plasma glucose, insulin, C-peptide
AC
173
NU
165
174
and amylin, followed by p-values for the preload, time and time by preload interaction effects are
175
shown in Table 1.
176
Pre-meal Mean Plasma Concentrations
177
Over the pre-meal period (0-30 min), mean plasma concentrations of glucose, insulin, C-
178
peptide and amylin were higher (P < 0.0001) after glucose preloads compared with WP and
179
control (Table 1). Both doses of WP increased insulin and C-peptide, however only the 20 g WP
180
increased amylin concentrations above control (P < 0.0001).
10
ACCEPTED MANUSCRIPT 181
Pre-meal concentrations of glucose, insulin, C-peptide (P < 0.0001) and amylin (P = 0.002) were affected by a time by preload interaction (Table 1). One-way ANOVA at each time
183
showed that preloads of glucose, but not WP, increased plasma glucose concentrations in a dose-
184
dependent manner (P < 0.0001) (Figure 1 A). Higher concentrations of insulin and C-peptide
185
after both doses of glucose were observed at 10 min (P < 0.05), 20 min (P < 0.0001) and 30 min
186
(P < 0.0001) (Figure 1 B). Only 20 g WP increased insulin concentrations (P < 0.0001), but C-
187
peptide concentrations were higher after both doses of WP (P < 0.0001) at 20 and 30 min
188
compared to the control, but less than equivalent doses of glucose (Figure 1 C). Amylin
189
concentrations were higher after 20 g WP and both glucose preloads than after 10 g WP or
190
control (Table 1). At 20 min, glucose preloads (P = 0.0008) and at 30 min, glucose preloads and
191
20 g WP (P < 0.0001) increased amylin concentrations compared to control (Figure 1 D).
192
Post-meal Mean Plasma Concentrations
RI P
SC
NU
MA
ED
PT
193
T
182
Over the post-meal period (50-230 min), mean plasma glucose concentrations were lower (P = 0.0006) than control after WP and glucose preloads, which were not different from each
195
other (Table 1). Mean insulin concentrations were lower (P = 0.0003) after 20 g WP than both
196
glucose preloads, and lower after 10 g WP than 20 g glucose. There was no difference between
197
control and WP preloads. Mean C-peptide concentrations were higher (P < 0.0001) after glucose
198
than after WP, and after 20 g glucose than control. Post-meal amylin concentrations were not
199
affected by preload, but were affected similarly by time (P = 0.006) (Table 1).
200
AC
CE
194
Post-meal plasma concentrations of glucose (P < 0.005) and C-peptide (P = 0.03), but not
201
insulin, were affected by a time by preload interaction (Table 1). One-way ANOVA at each time
202
showed that plasma glucose concentrations were lower after both WP doses and 10 g glucose
203
preloads at 60 min (P = 0.003), and after 20 g WP at 70 min (P < 0.05) compared to control
11
ACCEPTED MANUSCRIPT (Figure 1 A). Plasma glucose concentrations at 200 min were lower after 10 g compared to 20 g
205
glucose (P < 0.04). Plasma insulin concentrations, after an initial post-meal rise from 50-70 min
206
decreased to 230 min (Figure 1 B). While there was no difference between WP and control at
207
any of the post-meal times, C-peptide concentrations were higher after 20 g glucose compared
208
with control and WP at 50 min (P < 0.0001), 60 min (P < 0.002) and 70 min (P = 0.0002), with
209
WP at 80 min (P = 0.0009), with control and 20 g WP at 110 min (P = 0.002), and with 10 g
210
glucose and 10 g WP at170 min (P = 0.01) (Figure 1 C). The 10 g glucose preload led to a
211
greater C-peptide concentration compared with control at 50 min (P < 0.0001) and compared
212
with 20 g WP at 70 min (P = 0.0002) (Figure 1 C).
213
Total Mean Plasma Concentrations
MA
NU
SC
RI P
T
204
Over the entire pre- and post-meal period (0-230 min), mean plasma glucose
ED
214
concentrations were lower after WP, but higher after glucose, compared to control (P < 0.0001)
216
(Table 1). Mean plasma concentrations of insulin and C-peptide after WP were lower than after
217
glucose and not different from control (P < 0.0001). Mean plasma amylin concentrations were
218
higher (P = 0.0002) after both glucose and the 20 g WP preloads compared with control (Table
219
1).
221 222
CE
AC
220
PT
215
PLASMA GLP-1, GIP, PYY, CCK AND GHRELIN CONCENTRATIONS Pre-meal, post-meal and total mean concentrations of plasma concentrations of
223
gastrointestinal hormones, followed by p-values for the preload, time and time by preload
224
interaction effects are shown in Table 2.
225
Pre-meal Mean Plasma Concentrations
12
ACCEPTED MANUSCRIPT 226
During the pre-meal period (0-30 min), both doses of WP led to higher mean plasma GLP-1 concentrations than the equivalent dose of glucose or the control (P < 0.0001) (Table 2).
228
Mean plasma GIP concentrations were higher (P = 0.0002) after the treatments than control, but
229
did not differ from each other. Mean plasma PYY concentrations (P = 0.01) were higher than
230
control only after 20 g WP. Pre-meal CCK concentrations were not affected by preloads. Mean
231
plasma concentrations of ghrelin were not different from the preloads compared to control,
232
however, 20 g glucose suppressed (P < 0.05) mean ghrelin concentrations compared with 10 g
233
WP (Table 2).
NU
SC
RI P
T
227
Pre-meal plasma concentrations of GLP-1 (P = 0.01) and GIP were affected by a time by
235
preload interaction (Table 2). Plasma concentrations of GLP-1 were higher after 20 g WP and 20
236
g glucose at 20 min (P = 0.0004), and after 20 g WP at 30 min (P = 0.0001) than control (Figure
237
3 A). Plasma GIP concentrations were higher after all preloads at 20 min (P < 0.0001), and after
238
all preloads except 10 g glucose at 30 min (P = 0.004) than the control (Figure 3 B).
ED
PT
Pre-meal concentrations of PYY and ghrelin were not affected by a time by preload
CE
239
MA
234
interaction. Pre-meal mean CCK concentrations were not affected by time or preload, but there
241
was an interaction (P < 0.04) (Table 2), because the response to the preloads, while not different
242
among them, changed over time.
243
Post-meal Concentrations
244
AC
240
Over the post-meal period (60-230 min), mean plasma concentrations of GLP-1 and PYY
245
were higher (P < 0.0001) after WP than glucose (Table 2). Compared to control, 20 g WP
246
resulted in higher concentrations of PYY (P < 0.0001) and lower GIP (P = 0.03). All preloads
247
raised mean plasma CCK concentrations above control (P < 0.0001). Mean plasma ghrelin
248
concentrations were lower (P < 0.002) only after 20 g glucose compared with 10 g WP (Table 2).
13
ACCEPTED MANUSCRIPT Post-meal plasma concentrations of GLP-1 (P < 0.0001) and PYY (P = 0.0009) were
249
affected only by time, rising to 80 min and then decreasing to 230 min. There was no time by
251
preload interaction effects on these hormones (Table 2).
252
Total Mean Plasma Concentrations
RI P
T
250
Over the entire pre- and post-meal period (0-230 min), mean concentrations of GLP-1
253
and PYY were higher (P < 0.0001) after both doses of WP compared with glucose and control
255
(Table 2). However, mean GIP was not affected by preloads. Mean concentrations of CCK were
256
higher (P < 0.0001) after both glucose and WP than the control. Mean ghrelin concentrations
257
were lower (P = 0.0001) after 20 g glucose than 10 g WP (Table 2).
MA
NU
SC
254
258
GASTRIC EMPTYING RATE (PLASMA PARACETAMOL CONCENTRATIONS)
ED
259
Pre-meal (0-30 min) concentrations of paracetamol were affected by preload (P < 0.0001)
261
and time (P < 0.0001), but there was no time by preload interaction. Mean plasma concentrations
262
of paracetamol were lower after both doses of WP compared to control and 10 g glucose (Figure
263
4).
265 266 267
CE
AC
264
PT
260
Post-meal (50-230 min) concentrations of paracetamol decreased with time (P < 0.0001), but were not affected by preloads. Over the entire pre- and post-meal period (0-230 min), mean plasma paracetamol concentrations were lower after WP compared to 10 g glucose (P < 0.004).
268 269
DISCUSSION
270
The hypothesis that the post-meal plasma glucose concentrations after pre-meal
271
consumption of WP are determined in part by mechanisms beyond insulin is supported by this
14
ACCEPTED MANUSCRIPT study. Both WP and glucose preloads similarly reduce post-meal glycemia. However, their
273
mechanism of action differed. For the total duration of the study, WP resulted in lower mean
274
plasma glucose, insulin and C-peptide, but higher GLP-1 and PYY concentrations than glucose
275
preloads.
RI P
276
T
272
Several lines of evidence show that lower post-meal glycemia after WP, unlike glucose, occurs in part by insulin-independent mechanisms. First, these results are consistent with
278
previous studies indicating that consumption of WP prior to a meal [13] and or fed with CHO
279
[14] improves post-meal glycemia without an increase in post-meal insulin concentrations.
280
However the results are novel not only because they show that relatively small amounts are
281
efficacious when consumed before a meal, but also show that the lower blood insulin
282
concentrations did not occur through alterations in the balance of the kinetics of insulin secretion
283
and extraction. The pre-meal consumption of WP led to lower pre- and post-meal plasma
284
concentrations of glucose, but also of both insulin and C-peptide (Table 1). Because blood
285
insulin concentrations are a product of both secretion and liver extraction C-peptide was
286
measured. C-peptide is secreted in equimolar concentrations with insulin from pancreatic ß cells
287
but unlike insulin is not extracted by the liver. Therefore, the lower plasma concentrations of C-
288
peptide are an indication of lower insulin secretion [20]. When expressed relative to insulin, it is
289
also an indicator of hepatic insulin extraction by the liver. These ratios were similar for WP and
290
glucose, indicating that insulin extractions rates were unchanged (Figure 5) [8][20].
291
Furthermore, the post-meal ratios of C-peptide/insulin were similar after WP and glucose
292
preloads and the control, but glucose concentrations were lowered after both WP and glucose;
293
demonstrating that insulin-independent mechanisms contributed to post-meal regulation of blood
294
glucose concentrations.
AC
CE
PT
ED
MA
NU
SC
277
15
ACCEPTED MANUSCRIPT 295
Second, pre-meal consumption of WP, compared with glucose preloads, led to higher plasma concentrations of GLP-1 and PYY (Table 2). GLP-1 [21] and PYY [22] inhibit gut
297
motility and slow gastric emptying and both rapidly cross the blood-brain barrier (BBB) to
298
directly transmit signals that inhibit gastric emptying. Their increased blood concentration may
299
be explained by both increased synthesis in enteroendocrine L-cells but also by an inhibitory
300
action of WP on dipeptidyl peptidase IV (DPP-IV) which rapidly breaks down circulating
301
peptides[23-25] [7]. Additionally, GLP-1 receptors in the stomach regulate gastric acid secretion
302
and slow motility through ascending vagal afferent signals to the CNS [26, 27]. Taken together,
303
these actions are consistent with the 27% lower pre-meal gastric empting rate after WP compared
304
to glucose and the water control (Figure 4).
RI P
SC
NU
MA
Third, the increase in amylin concentrations after WP, similar to glucose (Table 1), has
ED
305
T
296
not been shown previously, but may be an additional factor in the improved glucose control
307
without additional insulin. Amylin is secreted simultaneously with insulin by the ß-cell with the
308
amylin to glucose ratio of approximately 1:100 [28]. Amylin affects gastric emptying [29-32]
309
and also regulates glucose homeostasis [33, 34] by acting centrally to suppress nutrient-
310
stimulated glucagon secretion from the α-cells [35], which in turn suppresses the release of
311
endogenous hepatic glucose [29-32].
312
AC
CE
PT
306
Fourth, GLP-1 [36, 37] and PYY [38, 39] in the portal vein stimulate hepatic vagal
313
afferents and pancreatic vagal afferents that activate and enhance glucose disposal, thereby,
314
augmenting portal-mediated glucose clearance.
315
The plasma concentrations of ghrelin decreased with time by 30% after the preloads and
316
meal, with the lowest at 140 min (34%). Others have shown that WP suppresses ghrelin release
317
[40]. However, neither WP nor glucose suppressed pre-meal ghrelin concentrations compared
16
ACCEPTED MANUSCRIPT 318
with the control, possibly due to the small total energy content of the WP or glucose preloads
319
(40-80 kcal) [41]. There are some limitations in the study. First, the sample size of eight is relatively small,
T
320
but was based on previous studies of sample sizes required to detect treatment effects on short-
322
term physiological responses in healthy individuals [13]. However, it is unlikely this affected the
323
conclusion. Based on a calculation of sample size using the variability found in this study, post-
324
meal PYY concentrations after 10 g WP and control would require a sample size of 32 subjects
325
to identify a difference, if it existed. Secondly, the paracetamol absorption test is an indirect
326
method used to measure of liquid gastric emptying rate in humans [12, 42, 43] and provides a
327
reliable, reasonably accurate and inexpensive estimate [44], but it does not have the precision of
328
scintigraphy, which is technically challenging and requires expensive equipment and special
329
licensing for use of radioactive substances [45]. However, while the quantitative rates of
330
stomach emptying may not be as accurate, the primary purpose of the measure was to compare
331
the response to treatments, and differences were found. Third, total ghrelin accounting for both
332
active (acyl ghrelin) and inactive forms of ghrelin (des-acyl ghrelin) was measured in this study.
333
Active ghrelin is now recognized as the preferred measure as it relates more clearly to
334
functionality [46]. Fourth, because this study assessed the acute and short-term effect of WP on
335
glycemia and hormonal responses in healthy young men, the effectiveness of WP consumption
336
on long-term glycemic control is unclear. However, the results of this study adds to the
337
accumulative evidence that whey protein has potential in the dietary management of obesity and
338
T2D [7] and provides encouragement for both short and longer term studies in such individuals.
339 340
AC
CE
PT
ED
MA
NU
SC
RI P
321
In conclusion, WP consumption prior to a meal results in post-meal glucose control by both insulin-dependent and –independent mechanisms.
17
ACCEPTED MANUSCRIPT 341
344 345
We thank Drs. Paul Pencharz, Thomas Wolever, and Ravi Retnakaran for their
T
343
ACKNOWLEDGMENTS
intellectual contribution and constructive guidance during the research.
RI P
342
The authors’ responsibilities were as follows—TA, PHB and GHA: conceived and designed the study; GHA: applied for and received the grant from NSERC; TA and BLL:
347
prepared the ethics application, recruited the volunteers, conducted the clinical session TA, RK,
348
SP and BLL: performed the biochemical analyses; TA: obtained and collated the data and
349
performed the statistical analyses; all authors contributed to the writing of this manuscript.
AC
CE
PT
ED
MA
NU
SC
346
18
ACCEPTED MANUSCRIPT REFERENCES 350
1.
Gannon MC, Nuttall FQ, Neil BJ, Westphal SA. The insulin and glucose responses to meals of glucose plus various proteins in type II diabetic subjects. Metabolism 1988;
352
37(11):1081-1088. 2.
RI P
353
T
351
Karamanlis A, Chaikomin R, Doran S, Bellon M, Bartholomeusz FD, Wishart JM, Jones KL, Horowitz M, Rayner CK. Effects of protein on glycemic and incretin responses and
355
gastric emptying after oral glucose in healthy subjects. Am J Clin Nutr 2007; 86(5):1364-
356
1368.
NU
3.
Frid AH, Nilsson M, Holst JJ, Bjorck IM. Effect of whey on blood glucose and insulin
MA
357
SC
354
responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin
359
Nutr 2005; 82(1):69-75.
supplement decreases post-prandial glycemia. Nutr J 2009; 8:47.
361 362
Petersen BL, Ward LS, Bastian ED, Jenkins AL, Campbell J, Vuksan V. A whey protein
PT
4.
5.
Akhavan T, Panahi S, Anderson GH, Luhovyy BL. Application of dairy-derived
CE
360
ED
358
ingredients in food intake and metabolic regulation. In: Dairy-derived ingredients: Food
364
and nutraceutical uses. Edited by Corredig M. Cambridge, UK: Woodhead Publishing
365
Ltd; 2009; 212-237.
366
AC
363
6.
and satiety. J Am Coll Nutr 2007; 26(6):704S-712S.
367 368
7.
371
Jakubowicz D, Froy O. Biochemical and metabolic mechanisms by which dietary whey protein may combat obesity and Type 2 diabetes. J Nutr Biochem 2013; 24(1):1-5.
369 370
Luhovyy BL, Akhavan T, Anderson GH. Whey proteins in the regulation of food intake
8.
Lan-Pidhainy X, Wolever TM. The hypoglycemic effect of fat and protein is not attenuated by insulin resistance. Am J Clin Nutr 2010; 91(1):98-105.
19
ACCEPTED MANUSCRIPT 372
9.
Boirie Y, Dangin M, Gachon P, Vasson MP, Maubois JL, Beaufrere B. Slow and fast dietary proteins differently modulate postprandial protein accretion. Proc Natl Acad Sci
374
U S A 1997; 94(26):14930-14935. 10.
Nilsson M, Holst JJ, Bjorck IM. Metabolic effects of amino acid mixtures and whey
RI P
375
T
373
protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr
377
2007; 85(4):996-1004.
energy intake in lean men. Br J Nutr 2010; 104(8):1241-8.
379 380
Pal S, Ellis V. The acute effects of four protein meals on insulin, glucose, appetite and
NU
11.
12.
Hall WL, Millward DJ, Long SJ, Morgan LM. Casein and whey exert different effects on
MA
378
SC
376
plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr
382
2003; 89(2):239-248. 13.
Akhavan T, Luhovyy BL, Brown PH, Cho CE, Anderson GH. The Effect of Pre-meal
PT
383
ED
381
Consumption of Whey Protein and its Hydrolysate on Food Intake and Post-Meal
385
Glycemia and Insulin Responses in Young Adults. Am J Clin Nutr 2010; 91(4):966-975. 14.
Ma J, E. SJ, Cukier K, Maddox AF, Wishart JM, Clifton PM, Horowitz M, Rayner CK.
AC
386
CE
384
387
Effects of a protein ‗preload‘ on gastric emptying, glycemia, and gut hormones after a
388
carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 2009; 32(9):1600-
389
1602.
390
15.
WB Saunders and Co 1980:208-217.
391 392
Herman CP, Polivy J. Restrained eating. In: AJ Stunkard Ed. Obesity Philadelphia, PA:
16.
Akhavan T, Anderson GH. Effects of glucose-to-fructose ratios in solutions on subjective
393
satiety, food intake, and satiety hormones in young men. Am J Clin Nutr 2007;
394
86(5):1354-1363.
20
ACCEPTED MANUSCRIPT 395
17.
different amounts of intact and hydrolysed proteins. Br J Nutr 2008; 100(1):61-69.
396
18.
Hamedani A, Akhavan T, Samra RA, Anderson GH. Reduced energy intake at breakfast
T
397
Claessens M, Saris WH, van Baak MA. Glucagon and insulin responses after ingestion of
is not compensated for at lunch if a high-insoluble-fiber cereal replaces a low-fiber
399
cereal. Am J Clin Nutr 2009; 89(5):1343-1349.
20.
Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes & Metabolism 1984; 33:486-494.
403 404
NU
Comput Methods Programs Biomed 1996; 50(3):253-264.
401 402
Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion.
SC
19.
21.
MA
400
RI P
398
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic
406
effects in healthy humans. Am J Physiol 1997; 273(5 Pt 1):E981-988. Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR. Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 1984; 30(4):255-262.
408
23.
Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper
AC
409
PT
22.
CE
407
ED
405
410
S, Brubaker PL. Regulation of the biological activity of glucagon-like peptide 2 in vivo
411
by dipeptidyl peptidase IV. Nat Biotechnol 1997(15):673-677.
412
24.
characterization of human PYY(3-36) and PYY(1-36). Peptides 1989; 10(4):797-803.
413 414
Eberlein GA, Eysselein VE, Schaeffer M, al. e. A new molecular form of PYY: structural
25.
Gunnarsson PT, Winzell MS, Deacon CF, Larsen MO, Jelic K, Carr RD, Ahren B.
415
Glucose-induced incretin hormone release and inactivation are differently modulated by
416
oral fat and protein in mice. Endocrinology 2006; 147(7):3173-3180.
21
ACCEPTED MANUSCRIPT 417
26.
Schmidtler J, Dehne K, Allescher H-D, Schusdziarra V, Classen M, Holst JJ, Polack A, Schepp W. Rat parietal cell receptors for GLP-1-(7-36) amide: Northern blot, cross-
419
linking, and radioligand binding. Am J Physiol 1994; 267 (3 Pt 1):G423-G432. 27.
Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like
RI P
420
T
418
peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1
422
receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose
423
homeostasis. Diabetes & Metabolism 2004; 53(9):2492-2500. 28.
NU
424
SC
421
Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, Chang JK, Rizza RA. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic
426
humans. Diabetes 1990; 39(6):752-756. 29.
Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C,
ED
427
MA
425
Kolterman OG. A randomized study and open-label extension evaluating the long-term
429
efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care
430
2002; 25(4):724-730.
CE
30.
Wang F, Adrian TE, Westermark GT, Ding X, Gasslander T, Permert J. Islet amyloid
AC
431
PT
428
432
polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat
433
pancreatic islets. Am J Physiol 1999; 276(1 Pt 1):E19-24.
434
31.
Wang ZL, Bennet WM, Ghatei MA, Byfield PG, Smith DM, Bloom SR. Influence of
435
islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin
436
release from perifused rat islets. Diabetes 1993; 42(2):330-335.
437
32.
Degano P, Silvestre RA, Salas M, Peiro E, Marco J. Amylin inhibits glucose-induced
438
insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas. Regul
439
Pept 1993; 43(1-2):91-96.
22
ACCEPTED MANUSCRIPT 440
33.
Karhunen LJ, Juvonen KR, Huotari A, Purhonen AK, Herzig KH. Effect of protein, fat, carbohydrate and fibre on gastrointestinal peptide release in humans. Regul Pept 2008;
442
149(1-3):70-78. 34.
Reidelberger RD, Arnelo U, Granqvist L, Permert J. Comparative effects of amylin and
RI P
443
T
441
cholecystokinin on food intake and gastric emptying in rats. Am J Physiol Regul Integr
445
Comp Physiol 2001; 280(3):R605-611.
rats. Metabolism: Clinical and Experimental 1997; 46 (1):67-70.
447 448
Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in
NU
35.
36.
Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal
MA
446
SC
444
hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol
450
1996; 271(5 Pt 1):E808-E813.
ED
449
37.
Drucker DJ. The biology of incretin hormones. Cell Metabolism 2006; 3(3):153-165.
452
38.
van den Hoek AM, Heijboer AC, Corssmit EP, Voshol PJ, Romijn JA, Havekes LM, Pijl
PT
451
H. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet.
454
Diabetes & Metabolism 2004; 53(8):1949-1952. 39.
AC
455
CE
453
Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY(3-36) reduces
456
food intake and body weight and improves insulin sensitivity in rodent models of diet-
457
induced obesity. Am J Physiol Regul Integr Comp Physiol 2006; 291(2):R367-375.
458
40.
Bowen J, Noakes M, Clifton PM. Appetite hormones and energy intake in obese men
459
after consumption of fructose, glucose and whey protein beverages. Int J Obes (Lond)
460
2007; 31(11):1696-1703.
23
ACCEPTED MANUSCRIPT 461
41.
Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, Weigle DS. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not
463
predict intermeal interval in humans. J Clin Endocrinol Metab 2004; 89(3):1319-1324. 42.
Sanaka M, Kuyama Y, Yamanaka M. Guide for judicious use of the paracetamol
RI P
464
T
462
absorption technique in a study of gastric emptying rate of liquids. J Gastroenterol 1998;
466
33(6):785-791. 43.
Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a
NU
467
SC
465
marker of gastric emptying? A systematic literature study. Dig Dis Sci 2001;
469
46(10):2256-2262.
470
44.
MA
468
Naslund E, Bogefors J, Gryback P, Jacobsson H, Hellstrom PM. Gastric emptying: comparison of scintigraphic, polyethylene glycol dilution, and paracetamol tracer
472
assessment techniques. Scand J Gastroenterol 2000; 35(4):375-379. Deane AM, Fraser RJ, Chapman MJ. Prokinetic drugs for feed intolerance in critical
46.
CE
illness: current and potential therapies. Crit Care Resusc 2009; 11(2):132-143.
474 475
PT
45.
Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, Kasuga
AC
473
ED
471
476
M. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005;
477
54(1):18-24.
478
24
ACCEPTED MANUSCRIPT Table 1 Mean plasma concentrations of glucose, insulin, C-peptide, and amylin after the
Control
10 g Glucose
20 g Glucose
(mmol/L)
meal2 Post-
Preload
Time
Interaction
5.3 ± 0.1c
<0.0001
<0.0001
<0.0001
5.7 ± 0.1b
5.6 ± 0.1b
0.0006
<0.0001
<0.005
5.5 ± 0.1c
5.5 ± 0.1c
<0.0001
<0.0001
<0.0001
82.8 ± 9.1c
106.0 ± 13.6c
<0.0001
<0.0001
<0.0001
266.6 ± 13.4a
218.1 ± 11.3bc
208.5 ± 9.4c
0.0003
<0.0001
NS
5.0 ± 0.1c
6.5 ± 0.2b
6.8 ± 0.3a
6.0 ± 0.1a
5.7 ± 0.1b
6.0 ± 0.1b
5.7 ± 0.1b
6.0 ± 0.1a
6.0 ± 0.1a
36.4 ± 3.8d
153.1 ± 16.3b
207.9 ± 24.3a
229.8 ± 11.5bc
240.5 ± 11.8ab
170.3 ± 11.9c
213.6 ± 10.4b
248.6 ± 12.1a
176.5 ± 10.3c
177.0 ± 9.0c
<0.0001
<0.0001
<0.0001
530.7 ± 24.2d
1081.8 ± 73.8b
1280.3 ± 112.3a
772.4 ± 50.1c
847.8 ± 48.9c
<0.0001
<0.0001
<0.0001
1604.7 ± 47.7bc
1725.8 ± 45.7b
2024.9 ± 63.4a
1589.8 ± 44.4c
1558.2 ± 40.7c
<0.0001
<0.0001
0.03
1274.2 ± 59.4c
1527.6 ± 48.6b
1795.8 ± 65.0a
1338.3 ± 50.6c
1339.6 ± 45.3c
<0.0001
<0.0001
<0.0001
18.5 ± 2.6b
27.3 ± 3.5a
28.7 ± 3.6a
21.3 ± 2.2b
26.7 ± 3.5a
<0.0001
0.0004
0.002
35.7 ± 2.8
38.2 ± 3.1
39.5 ± 3.5
36.4 ± 2.6
35.8 ± 3.3
NS
0.006
NS
28.3 ± 2.3c
33.5 ± 2.4a
34.9 ± 2.6a
29.9 ± 2.0bc
31.9 ± 2.5ab
0.0002
<0.0001
<0.005
3
Pre-
(pmol/L)
meal Post-
ED
Insulin
(pmol/L)
meal Postmeal Total Pre-
CE
Pre-
AC
C-peptide
PT
meal Total
5.1 ± 0.1c
MA
meal
Total4
P (Two-way ANOVA)
SC
Pre-
(pM)
20 g WP
NU
Glucose
Amylin
10 g WP
RI P
Biomarkers
T
preloads1
meal Postmeal Total
1
All values are ± SEM. n = 8. Data were analyzed for pre-meal, post-meal and total for preload ,
time, and preload x time interaction by 2-factor ANOVA (Proc Mixed) and significance was assessed using Tukey's post hoc, P < 0.05 for all, NS (not significant) 25
ACCEPTED MANUSCRIPT 2
Pre-meal values are means of all plasma concentrations before the test meal and calculated from
0-30 min Post-meal values are means of all plasma concentrations after the test meal and calculated from
T
3
4
RI P
50-230 min for plasma glucose, insulin and C-peptide and from 60-230 for plasma amylin Total values are means of all plasma concentrations before and after the test meal and
AC
CE
PT
ED
MA
NU
SC
calculated from 0-230 min
26
ACCEPTED MANUSCRIPT Table 2 Mean plasma concentrations of gastrointestinal hormones after the preloads1
10 g WP
20 g WP
Preload
Time
Interaction
4.9 ± 0.4c
5.3 ± 0.4c
5.8 ± 0.4bc
5.9 ± 0.3b
7.2 ± 0.4a
<0.0001
0.01
6.4 ± 0.4b
5.9 ± 0.3b
6.3 ± 0.4b
8.0 ± 0.4a
RI P
<0.0001
8.5 ± 0.5a
<0.0001
5.8 ± 0.3c
5.6 ± 0.2c
6.1 ± 0.3c
7.1 ± 0.3b
7.9 ± 0.3a
<0.0001
<0.0001
NS
82.7 ± 9.7b
157.6 ± 14.5a
139.3 ± 14.8a
152.9 ± 15.1a
166.5 ± 13.5a
0.0002
0.002
<0.04
393.9 ± 21.1a
372.5 ± 17.7ab
367.4 ± 20.3ab
364.5 ± 16.1ab
319.6 ± 18.6b
0.03
<0.0001
NS
260.5 ± 24.3
280.4 ± 18.6
269.6 ± 20.1
273.8 ± 18.0
254.0 ± 15.8
NS
<0.0001
0.0021
199.6 ± 11.2b
202.1 ± 8.1ab
204.9 ± 9.0ab
223.0 ± 7.8ab
230.3 ± 11.3a
0.01
NS
NS
231.0 ± 10.3bc
223.2 ± 6.5c
220.4 ± 6.5c
249.6 ± 8.6ab
270.4 ± 12.7a
<0.0001
0.0009
NS
217.6 ± 7.8b
214.2 ± 5.2b
213.8 ± 5.4b
238.2 ± 6.2a
253.2 ± 9.1a
<0.0001
<0.0001
NS
100.2 ± 8.8
103.5 ± 9.1
101.5 ± 7.8
122.0 ± 10.0
114.0 ± 8.1
NS
NS
<0.04
77.8 ± 8.1b
127.5 ± 8.3a
113.8 ± 6.4a
123.5 ± 9.0a
123.0 ± 8.1a
<0.0001
NS
NS
87.4 ± 6.1b
117.2 ± 6.3a
108.6 ± 5.0a
122.9 ± 6.4a
119.1 ± 5.7a
<0.0001
NS
0.04
405.0 ± 42.2ab
444.0 ± 64.6ab
322.7 ± 27.0b
512.3 ± 95.7a
407.4 ± 61.8ab
<0.05
NS
NS
304.1 ± 30.3ab
340.5 ± 32.0ab
215.6 ± 21.6b
431.7 ± 78.1a
328.0 ± 35.1ab
<0.002
NS
NS
347.4 ± 26.0bc
384.8 ± 33.6ab
261.5 ± 18.2c
466.2 ± 60.3a
362.0 ± 33.3abc
0.0001
0.0006
NS
2
meal
Post3
Total4 GIP
Pre-
(pg/mL)
meal Post-
Total PYY
Pre-
(pg/ mL)
meal Post-
Total CCK
Pre-
(ng/mL)
meal Postmeal Total
Ghrelin
Pre-
(pg/mL)
meal
CE
meal
ED
meal
NU
meal
T
20 g Glucose
SC
(pg/mL)
Pre-
10 g Glucose
MA
GLP-1
Control
PT
Biomarkers
AC
P (Two-way ANOVA)
<0.0001
NS
Postmeal Total
27
ACCEPTED MANUSCRIPT 1
All values are ± SEM. n = 8. Data were analyzed for pre-meal, post-meal and total for preload ,
time, and preload x time interaction by 2-factor ANOVA (Proc Mixed) and significance was
Pre-meal values are means of all plasma concentrations before the test meal and calculated from
RI P
2
T
assessed using Tukey's post hoc, P < 0.05 for all, NS (not significant)
0-30 min
Post-meal values are means of all plasma concentrations after the test meal and calculated from
SC
3
4
NU
60-230 min
Total values are means of all plasma concentrations before and after the test meal and
AC
CE
PT
ED
MA
calculated from 0-230 min
28
ACCEPTED MANUSCRIPT FIGURE LEGENDS
480
FIGURE 1 Mean (± SEM) pre- and post-meal plasma concentrations of glucose (A), insulin (B),
481
C-peptide (C) and amylin (D) in 8 healthy men after intake of water (····Ӂ····), 10 g glucose
482
(····Δ····), 20 g glucose (····▲····), 10 g whey protein (—○—), and 20 g whey protein (—●—).
483
Different superscripts at each measured time are different between preloads (one-way ANOVA,
484
Proc Mixed, followed by Tukey‘s post hoc, P < 0.05).
SC
RI P
T
479
NU
485
FIGURE 2 Mean (± SEM) pre-meal, post-meal and total insulin secretion rate (pmol/kg/min)
487
calculated from plasma C-peptide concentrations (pmol/L) after the whey protein and glucose
488
preload consumption (n = 8). Two-factor repeated-measures ANOVA followed by Tukey‘s post
489
hoc was used to compare the effect of preloads (means with different superscripts at pre-meal (0-
490
30 min), post-meal (50-230 min) and total (0-230 min) are different, P < 0.0001).
PT
ED
MA
486
491
FIGURE 3 Mean (± SEM) pre-and post-meal plasma concentrations of GLP-1 (A) and GIP (B)
493
in 8 healthy men after intake of water (····Ӂ····), 10 g glucose (····Δ····), 20 g glucose (····▲····), 10
494
g whey protein (—○—), and 20 g whey protein (—●—). Different superscripts at each measured
495
time are different between preloads (one-way ANOVA, Proc Mixed, followed by Tukey‘s post
496
hoc, P < 0.05).
AC
CE
492
497 498
FIGURE 4 Mean (± SEM) pre-meal plasma concentrations of paracetamol after the whey
499
protein and glucose preload consumption (n = 8). Two-factor repeated-measures ANOVA
500
followed by Tukey‘s post hoc was used to compare the effect of preloads (means with different
29
ACCEPTED MANUSCRIPT 501
superscripts at pre-meal (0-30 min) are different, P < 0.0001) and time (P < 0.0001), but no
502
interaction effect.
T
503
FIGURE 5 Mean (± SEM) ratio of pre-meal and post-meal plasma concentrations of C-
505
peptide/insulin after the whey protein and glucose preload consumption (n = 8). Two-factor
506
repeated-measures ANOVA followed by Tukey‘s post hoc was used to compare the effect of
507
preloads (means with different superscripts at pre-meal (0-30 min) and post-meal (50-230 min)
508
are different, P < 0.05).
AC
CE
PT
ED
MA
NU
SC
RI P
504
509
30
510
AC
CE
PT
ED
MA
NU
SC
RI P
T
ACCEPTED MANUSCRIPT
31
MA
NU
SC
RI P
T
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
511
32
ED
MA
NU
SC
RI P
T
ACCEPTED MANUSCRIPT
AC
CE
PT
512
33
MA
NU
SC
RI P
T
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
513
34
SC
RI P
T
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
MA
NU
514
35